Gastrointestinal Cancer News

Conditional survival estimates may provide more accurate quantitative information than OS about the changing survival probability for patients undergoing liver resection for intrahepatic cholangiocarcinoma, according to study results.

TAS-102, an oral agent composed of trifluridine and tipiracil hydrochloride, significantly prolonged OS in patients with refractory metastatic colorectal cancer, according to the results of a randomized, double blind, phase 3 trial.

The FDA has granted fast track designation for the development of evofosfamide for the treatment of metastatic or locally advanced unresectable pancreatic cancer in patients who were previously untreated, the manufacturer announced today.

Taiwanese patients with chronic hepatitis B virus infection and newly diagnosed diabetes had an increased risk for hepatocellular carcinoma over time, according to study findings.

Comprehensive genomic profiling of advanced gastric carcinoma is feasible and leads to the detection of clinically relevant alterations known to benefit from targeted therapies, according to study results.

Can-Fite BioPharma Ltd. announced the European Medicines Agency approved a phase 2 clinical trial for CF102, a potential drug treatment for hepatocellular carcinoma, and has already dosed its first patient in Europe, according to a press release from the manufacturer.

Roche today announced that it was granted FDA approval for the cobas KRAS Mutation Test, a diagnostic test used to help determine appropriate therapy options for patients with metastatic colorectal cancer, according to a press release.

VIENNA — A new study presented at the 2015 International Liver Congress showed that cancer rates were higher in patients with hepatitis C virus infection vs. those without the infection, according to an analysis of the Kaiser Permanente Southern California cancer registry.

The addition of masitinib to gemcitabine significantly prolonged OS in patients with advanced pancreatic cancer who overexpressed ACOX1 or had baseline pain, according to the results of a randomized phase 3 study.

An estimated 4% of cancers in men and 7% of cancers in women are associated with obesity, according to the NCI.